Jump Financial’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jump Financial’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-47,800	Closed	-$306K	–	1746
2025 Q2	$306K	Buy	+47,800	New	+$232K	﹤0.01%	1409
2025 Q1	–	Sell	-104,342	Closed	-$394K	–	1560
2024 Q4	$394K	Buy	+104,342	New	+$491K	0.01%	1192
2024 Q3	–	Sell	-17,685	Closed	-$33.6K	–	1615
2024 Q2	$33.6K	Buy	+17,685	New	+$34.3K	﹤0.01%	1698
2024 Q1	–	Sell	-13,343	Closed	-$196K	–	1871
2023 Q4	$196K	Sell	13,343 -9,497	-42%	-$146K	0.01%	1573
2023 Q3	$418K	Sell	22,840 -118,607	-84%	-$2.51M	0.02%	1109
2023 Q2	$3.05M	Buy	+141,447	New	+$3.82M	0.11%	246

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Jump Financial's AMLX Position: Q3 2025 in Review

Jump Financial sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2025, closing a stake of 47,800 shares — an estimated $306K sold.

Jump Financial first reported a position in AMLX in Q2 2023 and held it in 6 quarters. The position peaked at $3.05M in Q2 2023. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

Jump Financial reported no remaining Amylyx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Jump Financial sold 47,800 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $306K.
Jump Financial first reported a position in Amylyx Pharmaceuticals in Q2 2023 and held it in 6 quarters.
Jump Financial's Amylyx Pharmaceuticals position peaked at $3.05M in Q2 2023.
169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on Jump Financial's 13F filing for Q3 2025, filed 13 Nov 2025.